Drugs / BELUDAVIMAB
BELUDAVIMAB
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04746183 | Jul 2020 → Mar 2027 expected | COVID-19 | University of Liverpool | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BELUDAVIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802220 ↗ |
| Known as | GSK-4182137 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802220 ↗ |
| Known as | VIR-7832 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04746183 ↗ |
| Modality | Monoclonal antibody | — CHEMBL4802220 ↗ |
| Route | Intravenous | “VIR-7832 will be administered by intravenous (IV) infusion over 1 hour.” NCT04746183 ↗ |